Breaking News
Get 40% Off 0
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks. Unlock full list
Close

Mediolanum Challenge Healthcare Equity Evolution L Accumulation (0P00000G0S)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.148 +0.070    +0.97%
15/05 - Closed. Currency in EUR ( Disclaimer )
Type:  Fund
Market:  Germany
ISIN:  IE0004479642 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 836.29M
Mediolanum Challenge Healthcare Equity Evolution L 7.148 +0.070 +0.97%

0P00000G0S Holdings

 
Comprehensive information about top holdings and Key Holding Information for the Mediolanum Challenge Healthcare Equity Evolution L (0P00000G0S) fund. Our Mediolanum Challenge Healthcare Equity Evolution L portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 1.510 2.990 1.480
Shares 98.480 98.480 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 18.932 21.892
Price to Book 4.780 4.021
Price to Sales 1.768 2.277
Price to Cash Flow 15.970 17.046
Dividend Yield 1.524 1.338
5 Years Earnings Growth 9.838 11.286

Sector Allocation

Name  Net % Category Average
Healthcare 98.950 94.888
Industrials 0.540 3.170
Basic Materials 0.360 1.279
Consumer Defensive 0.110 3.376
Financial Services 0.030 8.576

Region Allocation

  • North America
  • Latin America
  • Europe Developed
  • Asia
  • Australasia
  • Africa & Middle East
  • Emerging Markets
  • Developed Markets

Top Holdings

Number of long holdings: 134

Number of short holdings: 1

Name ISIN Weight % Last Change %
  UnitedHealth US91324P1021 7.03 517.23 -1.41%
  Eli Lilly US5324571083 6.41 783.18 +1.71%
AB International HC S1 EUR Acc LU0260062871 4.97 - -
  Novo Nordisk B DK0062498333 4.58 903.3 -1.05%
  db x-trackers MSCI Wd Health Care IE00BM67HK77 4.45 49.930 +0.32%
  Roche Holding Participation CH0012032048 2.73 237.10 +0.98%
  Merck&Co US58933Y1055 2.71 130.99 -0.15%
  Vertex US92532F1003 2.57 445.87 +0.15%
  GSK plc GB00BN7SWP63 2.48 1,775.00 0.00%
  Amgen US0311621009 2.36 314.54 +0.66%

Top Equity Funds by Mediolanum International Funds Limited

  Name Rating Total Assets YTD% 3Y% 10Y%
  IE00B2NLMV86 5.15B 4.56 -4.53 4.88
  IE00B2NLMX01 5.15B 4.41 -4.91 4.49
  IE00B2NLMW93 5.15B 6.06 -2.44 6.19
  IE0032082988 2.28B 6.94 5.16 6.65
  IE0004878413 2.27B 9.85 9.18 10.55
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P00000G0S Comments

Write your thoughts about Mediolanum Challenge Healthcare Equity Evolution L Accumulation
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email